A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Clinical trial NCT06100744 · RECRUITING

Trial details

NCT number: NCT06100744
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Juvenile Psoriatic Arthritis

Start date: 2024-07-08
Primary completion: 2026-09-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.